Fda Warns This Medication May Increase Your Risk Of Heart Problems
The FDA issued a statement in February, warning Americans that “preliminary results from an initial safety clinical trial” on Xeljanz showed an increased risk of serious heart-related problems as a result of the medication. This medication—which is an arthritis and ulcerative colitis drug classified under the generic name tofacitinib—was compared by the administration to another type of medication called a tumor necrosis factor (TNF) inhibitor, which also treats arthritis. According to the trial findings, Xeljanz also increases someone’s risk of cancer when compared to those treated with a TNF inhibitor instead....